MYC amplification and TERT expression in breast tumor progression
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsBodvarsdottir, Sigridur K
Jonasson, Jon G
Eyfjord, Jorunn E
MetadataShow full item record
CitationCancer Genet. Cytogenet. 2007, 176(2):93-9
AbstractThe complex roles of genomic instability, MYC oncogene amplification, activation of telomerase, and p53 function still remain to be fully described in breast tumors. MYC stimulates the telomerase catalytic subunit, TERT, which interacts with p53. Oncogene MYC amplification analysis was performed on 27 paraffin-embedded breast tumor samples by fluorescence in situ hybridization, selected on the basis of chromosomal instability. TERT immunostaining was performed on a larger group of breast tumor sections. All tumor samples were analyzed for TP53 mutation, genomic index, S-phase fraction, and pathological stages. Amplification of MYC was detected in 16 of 27 tumors (59%) and found to be associated with TNM stages I and II (P = 0.018), genomic index > 1.5 (P = 0.033), and S-phase fraction > 5% (P = 0.020). No association was found between MYC amplification and TERT immunostaining or TP53 mutations. Analysis of TERT in 103 primary breast tumors showed > 50% nuclei immunostaining in 58% of cases. High TERT immunostaining associated with genomic index > 1.5 (P = 0.017), high S-phase fraction (P = 0.056), and TP53 mutations (P = 0.030). No association was found between TERT staining and TNM stages. This study supports early involvement of MYC amplification in breast tumor progression. Both MYC amplification and TERT expression appear to be associated with high genomic instability and proliferation. TERT association with TP53 mutations indicates that TERT activity is downregulated by functional p53 protein in breast tumors.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues.
- Authors: Hines WC, Fajardo AM, Joste NE, Bisoffi M, Griffith JK
- Issue date: 2005 Sep
- MYC is amplified in BRCA1-associated breast cancers.
- Authors: Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstråle KK, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL, Olopade OI
- Issue date: 2004 Jan 15
- The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
- Authors: Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, Serrano S, Solé F
- Issue date: 2006 Mar
- Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
- Authors: Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ
- Issue date: 2003 Sep
- Comparative polymerase chain reaction analysis of c-myc amplification on archival breast fine-needle aspiration materials.
- Authors: Rao JY, Apple SK, Jin Y, Lin S, Nieberg RK, Hirtschowitz SL
- Issue date: 2000 Feb